Post by
enriquesuave on Dec 20, 2020 3:24pm
End Points
The Primary end point is CR at any time point. The Secondary endpoint is duration of CR status which is how long patient remains CR up to 365 days after CR was first determined. Tertiary endpoint of safety or adverse events. IMO most patients who are CR should be determined at day 30 or 90 depending on whether they do a cystoscope exam at 30 days as well as 90 days as well as urine cytology. It would seem that any patient who is determined to be CR at 30 days, then that would probably be the result of a complete tumor destruction. Anyone who would maybe be CR at 90 but not at 30 days would maybe be complete destruction only after development of an immune response after partial tumor destruction by PDT. All imo. I'm pretty sure they are doing cystoscope exams at day 30 as well. 2021 could and hopefully will be our best year ever to date. All imo
Comment by
floatinketucky on Dec 20, 2020 9:55pm
I agree that we are on the cusp of a major move up. Looking the milestones meet justify the market considering the value currently in the stock. We will break our 5 year range soon! TLTFF Long
Comment by
CancerSlayer on Dec 21, 2020 10:19am
I agree. 2021 should be the breakout year, especially with the US on board. I'd also anticipate PIs & medical staff will have completed their Covid-19 vaccinations in Q1 (& the general population hopefully by summer). The above should make for a much smoother path & allow easier enrollment/treatment moving forward imo.